FMP
Medtronic Beats Q4, Hikes Dividend, But 2026 Outlook Disappoints
May 21, 2025 3:22 PM - Davit Kirakosyan
Image credit: FMP
Medtronic (NYSE:MDT) reported better-than-expected fiscal Q4 earnings and revenue, while unveiling plans to spin off its Diabetes business. However, full-year guidance for fiscal 2026 came in below analyst expectations.
For the quarter, the medical device giant posted EPS of $1.62, beating the $1.58 consensus. Revenue rose 3.6% year-over-year to $8.93 billion, topping the $8.82 billion forecast. Adjusted operating margin improved to 27.8%, up from 26.9% a year ago, though slightly shy of estimates. The company also increased its quarterly dividend to $0.71 per share, bringing the annualized payout to $2.84.
Looking ahead, Medtronic expects fiscal 2026 EPS between $5.50 and $5.60, missing the Street’s $5.83 estimate. The company guided for approximately 5% organic revenue growth.
Other Blogs
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
Two great Software Platform Stocks Similar to Palantir (PLTR)
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...
